FDA
-
-
-
-
-
-
-
UroGen files NDA with FDA for bladder cancer drug UGN-103
-
-
-
-
-
-
-
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
-
-
-
-
-
-
-
UroGen reports 64.5% three-year response rate for ZUSDURI bladder cancer drug
-
-
-
-
-
-
-
UroGen launches ZUSDURI as revenue rises 21% in 2025
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
-
-
-
-
-
-
-
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
-
330,652 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

